UAB Digital Repository of Documents 2 records found  Search took 0.01 seconds. 
1.
12 p, 506.4 KB Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia / Stein, Eytan M. (Memorial Sloan Kettering Cancer Center (New York)) ; DeAngelo, Daniel J. (Dana-Farber Cancer Institute (Boston, Massachusetts)) ; Chromik, Jörg (Goethe University Frankfurt) ; Chatterjee, Manik (University Hospital of Würzburg) ; Bauer, Sebastian (German Consortium of Translational Cancer Research (DKTK)) ; Lin, Chia-Chi (National Taiwan University Hospital (Taipei, Taiwan)) ; Suárez, Cristina (Vall d'Hebron Institut d'Oncologia) ; de Vos, Filip (University Medical Center Utrecht) ; Steeghs, Neeltje (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ; Cassier, Philippe A. (Léon Bérard Center) ; Tai, David (National Cancer Center Singapore) ; Kiladjian, Jean-Jacques (Université de Paris) ; Yamamoto, Noboru (National Cancer Center Hospital (Tokyo, Japó)) ; Mous, Rogier (University Medical Center Utrecht) ; Esteve Reyner, Jordi (Hospital Clínic i Provincial de Barcelona) ; Minami, Hironobu (Kobe University Graduate School of Medicine and Hospital (Japó)) ; Ferretti, Stephane (Novartis Institutes for Biomedical Research) ; Guerreiro, Nelson (Novartis Institutes for Biomedical Research) ; Meille, Christophe (Novartis Institutes for Biomedical Research) ; Radhakrishnan, Rajkumar (Novartis Healthcare Private Limited (Hyderabad, India)) ; Pereira, Bernard (Novartis Institutes for BioMedical Research (Cambridge, Massachusetts)) ; Mariconti, Luisa (Novartis Institutes for Biomedical Research) ; Halilovic, Ensar (Novartis Institutes for BioMedical Research (Cambridge, Massachusetts)) ; Fabre, Claire (Novartis Institutes for Biomedical Research) ; Carpio Segura, Cecilia del Carmen (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
This phase I, dose-escalation study investigated the recommended dose for expansion (RDE) of siremadlin, a p53-MDM2 inhibitor, in patients with wild-type TP53 advanced solid or hematologic cancers. Initial dosing regimens were: 1A (day 1; 21-day cycle; dose 12. [...]
2021 - 10.1158/1078-0432.CCR-21-1295
Clinical Cancer Research, Vol. 28 (december 2021) , p. 870-881  
2.
14 p, 2.2 MB Early euprimates already had a diverse locomotor repertoire: Evidence from ankle bone morphology / Monclús-Gonzalo, Oriol (Institut Català de Paleontologia Miquel Crusafont) ; Alba, David M.. (Institut Català de Paleontologia Miquel Crusafont) ; Duhamel, Anaïs (University of Lyon) ; Fabre, Anne-Claire (University of Bern) ; Marigó Cortés, Judit (Universitat Autònoma de Barcelona. Departament de Geologia)
The morphological adaptations of euprimates have been linked to their origin and early evolution in an arboreal environment. However, the ancestral and early locomotor repertoire of this group remains contentious. [...]
2023 - 10.1016/j.jhevol.2023.103395
Journal of human evolution, Vol. 181 (August 2023) , art. 103395  

See also: similar author names
20 Fabre, C.
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.